Krilogy Financial LLC Purchases 8,801 Shares of Repligen Corporation $RGEN

Krilogy Financial LLC increased its position in shares of Repligen Corporation (NASDAQ:RGEN) by 81.8% during the first quarter, Holdings Channel reports. The institutional investor owned 19,557 shares of the biotechnology company’s stock after purchasing an additional 8,801 shares during the period. Krilogy Financial LLC’s holdings in Repligen were worth $2,485,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also added to or reduced their stakes in the company. Iron Triangle Partners LP bought a new stake in shares of Repligen during the third quarter worth about $36,091,000. Hudson Bay Capital Management LP bought a new position in Repligen in the 3rd quarter valued at about $2,807,000. Massachusetts Financial Services Co. MA acquired a new position in Repligen during the 4th quarter valued at about $199,176,000. Cinctive Capital Management LP acquired a new position in Repligen during the 3rd quarter valued at about $3,398,000. Finally, Royce & Associates LP increased its holdings in Repligen by 66.1% during the 3rd quarter. Royce & Associates LP now owns 148,658 shares of the biotechnology company’s stock worth $19,871,000 after purchasing an additional 59,136 shares in the last quarter. Institutional investors own 97.64% of the company’s stock.

Analysts Set New Price Targets

RGEN has been the subject of several analyst reports. Canaccord Genuity Group lowered their price objective on Repligen from $165.00 to $145.00 and set a “hold” rating for the company in a research note on Monday, April 20th. UBS Group cut their target price on Repligen from $200.00 to $195.00 and set a “buy” rating on the stock in a research report on Wednesday, February 25th. Royal Bank Of Canada assumed coverage on Repligen in a report on Thursday, May 14th. They set an “outperform” rating and a $160.00 price target for the company. Wall Street Zen lowered Repligen from a “buy” rating to a “hold” rating in a research report on Saturday, February 28th. Finally, Jefferies Financial Group restated a “hold” rating and set a $142.00 price objective on shares of Repligen in a research note on Tuesday, May 5th. Two investment analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Repligen presently has an average rating of “Moderate Buy” and a consensus target price of $164.64.

Repligen Trading Up 9.5%

NASDAQ:RGEN opened at $138.40 on Thursday. Repligen Corporation has a 52 week low of $100.99 and a 52 week high of $175.77. The firm has a 50-day moving average price of $122.25 and a two-hundred day moving average price of $135.60. The company has a debt-to-equity ratio of 0.26, a quick ratio of 7.78 and a current ratio of 9.20. The firm has a market cap of $7.81 billion, a price-to-earnings ratio of 153.78, a price-to-earnings-growth ratio of 2.43 and a beta of 1.09.

Repligen (NASDAQ:RGEN) last announced its earnings results on Tuesday, May 5th. The biotechnology company reported $0.48 earnings per share for the quarter, topping analysts’ consensus estimates of $0.38 by $0.10. The firm had revenue of $194.25 million for the quarter, compared to the consensus estimate of $192.05 million. Repligen had a return on equity of 4.88% and a net margin of 6.73%.The company’s revenue was up 14.8% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.39 EPS. Repligen has set its FY 2026 guidance at 1.970-2.050 EPS. On average, equities analysts expect that Repligen Corporation will post 1.99 earnings per share for the current fiscal year.

Repligen Company Profile

Repligen Corporation (NASDAQ:RGEN) is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen’s offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company’s core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.